quinta-feira, 12 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Does Amazon's Andy Jassy Know Something Wall Street Doesn't? He Just Made a Game-Changing AI Prediction -- and It's Excellent News for Investors.

View original at nasdaq.com
Does Amazon's Andy Jassy Know Something Wall Street Doesn't? He Just Made a Game-Changing AI Prediction -- and It's Excellent News for Investors…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We have very clear and significant demand signals for AI services

    60% confidence
  • Amazon is generating revenue from new capacity as soon as it becomes available

    60% confidence
  • The 10 best stocks for investors to buy now could produce monster returns, but Amazon wasn't one of them

    60% confidence
  • Amazon is able to monetize new capacity instantly as it becomes available

    60% confidence
  • Stock Advisor's total average return is 911%, a market-crushing outperformance compared to 186% for the S&P 500

    60% confidence
  • AI may help push AWS to $600 billion in annual revenue within a decade, nearly double his earlier forecast

    60% confidence
  • Amazon is not spending $200 billion in capex just hoping AI will be big, but based on clear demand

    60% confidence

Data points we hold from this source

Amazon Web Services · operating income contribution57 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com